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Abstract
Background
HIV-infected individuals have deficient responses to Yellow Fever vaccine (YFV) and may
be at higher risk for adverse events (AE). Chronic immune activation–characterized by low
CD4/CD8 ratio or high indoleamine 2,3-dioxygenase-1 (IDO) activity—may influence vac-
cine response in this population.
Methods
We prospectively assessed AE, viremia by the YFV virus and YF-specific neutralizing anti-
bodies (NAb) in HIV-infected (CD4>350) and -uninfected adults through 1 year after vacci-
nation. The effect of HIV status on initial antibody response to YFV was measured during
the first 3 months following vaccination, while the effect on persistence of antibody response
was measured one year following vaccination. We explored CD4/CD8 ratio, IDO activity
(plasma kynurenine/tryptophan [KT] ratio) and viremia by Human Pegivirus as potential pre-
dictors of NAb response to YFV among HIV-infected participants with linear mixed models.
Results
12 HIV-infected and 45-uninfected participants were included in the final analysis. HIV was not
significantly associated with AE, YFV viremia or NAb titers through the first 3 months following
vaccination. However, HIV–infected participants had 0.32 times the NAb titers observed for
HIV-uninfected participants at 1 year following YFV (95% CI 0.13 to 0.83, p = 0.021), indepen-
dent of sex, age and prior vaccination. In HIV-infected participants, each 10% increase in
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CD4/CD8 ratio predicted a mean 21% higher post-baseline YFV Nab titer (p = 0.024). Simi-
larly, each 10% increase in KT ratio predicted a mean 21% lower post-baseline YFV Nab titer
(p = 0.009). Viremia by Human Pegivirus was not significantly associated with NAb titers.
Conclusions
HIV infection appears to decrease the durability of NAb responses to YFV, an effect that
may be predicted by lower CD4/CD8 ratio or higher KT ratio.
Author Summary
Yellow Fever (YF) vaccine is considered one of the most effective vaccines ever produced.
However, previous studies suggest that HIV impairs YF vaccine response. In this study,
we assessed if HIV infection impacts the risk of adverse events and could reduce antibody
response to YF vaccine. We explored if laboratory markers of persistent inflammation,
frequently present among HIV-infected patients, could predict antibody response to YF
vaccine in this population. We found that HIV had no significant effect on adverse events
or levels of antibodies through 3 months after vaccination, but this may be limited by the
small sample size of 12 HIV-infected and 45-uninfected participants in the study. How-
ever, we were able to show that, compared to HIV-uninfected participants, HIV–infected
patients had lower antibody titers 1 year following YF vaccine even after statistical adjust-
ment for the potential effects of sex, age and prior vaccination. Persistent inflammation
seems to reduce YF vaccine antibody response in HIV-infected participants. In conclu-
sion, HIV-infected individuals have impaired antibody response to YFV due to a poorer
persistence of antibodies, despite a seemingly normal initial response. HIV-infected
patients at permanent or recurring risk of YF infection may benefit from a booster dose of
YF vaccine.
Introduction
Effective antiretroviral treatment (ART) drastically improved clinical outcomes for people liv-
ing with HIV. However, these patients still present increased risk of death, higher prevalence
of comorbidities, and impaired responses to vaccines [1–6]. Prior studies have shown impaired
Yellow Fever vaccine (YFV) immunogenicity among HIV-infected persons is associated with
detectable HIV viral load (VL) [7–12] and lower CD4 T cell counts [11]. However, it is still
unclear whether reduced YFV antibody response among HIV-infected individuals is caused
by a blunted initial response, decreased persistence of antibodies, or both. Moreover, predic-
tors of YFV immunogenicity among patients with effective and early ART are not well known.
More recently, studies including patients with early initiation of ART have suggested a neg-
ative effect of persistent immune activation on responses to Influenza vaccine [13, 14], Neis-
seria meningitis vaccine [15] and YFV [16, 17] in both HIV-infected and–uninfected
individuals. This is consistent with previous studies that demonstrate excessive immune acti-
vation and inflammation predict residual morbidity and mortality in treated HIV-infected
patients [18–20]. A range of biomarkers has been used in different settings to quantify persis-
tent immune activation [20]. One increasingly appraised indirect biomarker is the ratio of
CD4 to CD8 T lymphocytes, or CD4/CD8 ratio. Previous studies have shown that CD4/CD8
ratio correlates with markers of CD8 T cell activation, and a lower CD4/CD8 ratio predicts
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higher risk of non-Aids events and mortality among ART-treated HIV-infected patients [21–
23]. Furthermore, a low CD4/CD8 ratio is also strongly associated with the activity of Indolea-
mine 2,3-dioxygenase-1 (IDO), an enzyme expressed by activated myeloid cells in HIV and
other inflammatory conditions that causes adaptive immune defects. IDO catabolizes trypto-
phan (T) to kynurenine (K) and other metabolites that may contribute to proliferative lympho-
cyte defects, regulatory T cell expansion, microbial translocation and immune activation in
treated HIV infection [24]. Therefore, elevated IDO activity (as measured by plasma KT ratio)
may also indicate adaptive immune dysfunction in this population. Finally, chronic co-infec-
tion with Human Pegivirus has been associated with reduced innate and adaptive immune
activation among HIV-infected patients in prior studies [25–27].
An additional relevance of YFV in HIV-infected patients concerns the theoretic higher risk
of YFV-associated severe adverse events (AE) in this population [28, 29]. YFV is produced
from the 17D or 17DD attenuated viral strains, and although mechanisms for YFV-associated
AE are not completely elucidated, immunosuppressed patients and persons at extremes of age
are considered at increased risk [28, 30]. It is hypothesized that immune response fails to con-
tain the vaccine virus replication, typically seen only in the first 3–5 days after vaccination,
leading to uncontrolled viral dissemination and clinical disease [31].
In this study, HIV-infected patients and controls referred to receive YFV were enrolled and
prospectively followed for 1 year after vaccination. We addressed clinical and laboratory AE
and viremia by the YFV virus. In addition, we investigated if HIV status was associated with
titers of Yellow Fever (YF)-specific neutralizing antibodies (NAb) in the first 3 months follow-
ing vaccination (henceforth defined initial YFV immunogenicity) and one year following vac-
cination (henceforth defined persistence of YFV immunogenicity). Finally, we explored if
correlates of immune activation including CD4/CD8 ratio, KT ratio, and Human Pegivirus
co-infection predict YFV response among HIV-infected subjects.
Methods
Study population
Subjects aged 18 years old and older who were referred to receive YFV at Clinics Hospital in
Sao Paulo, Brazil, between October 2011 and April 2014 were screened for participation.
Potential participants were evaluated by an attending physician who determined whether
YFV was indicated based on risk of exposure to wild YF and YFV contraindications as defined
by National Guidelines. The Guidelines do not recommend YFV to pregnant and breastfeed-
ing women, subjects under immunosuppressive medications and patients with conditions
such as cancer and thymus dysfunction. HIV-infected patients with a CD4 T cell count above
350/ml measured in the previous 4 months were considered eligible for vaccination. At enroll-
ment, HIV-negative persons underwent a rapid HIV-test.
For both groups, participants with immunosuppressive conditions other than HIV infec-
tion were excluded. These included diabetes, chronic liver or kidney diseases, any type of can-
cer (except resolved Kaposi Sarcoma), and use of systemic immunosuppressive therapy in the
last 3 months. Female participants in reproductive age underwent a pregnancy test at
enrollment.
Study procedures
At enrollment, medical history and date of previous YFV was obtained, if applicable. A blood
sample was collected for assessment of baseline complete blood count and liver enzymes, CD4
and CD8 T cell counts, plasma KT ratio and Human Pegivirus viremia. HIV-infected partici-
pants had HIV VL measured at baseline and all subsequent visits. Participants were followed
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on days 3, 5, 7, 14, 28, 56, 84, and 365 after vaccination. We measured viremia by the YFV
virus on days 3, 5, 7, and 14 after vaccination, and measured titers of YF-specific NAb at
baseline and on days 7, 14, 28, 56, 84 and 365 after vaccination. We also collected data on
spontaneous and solicited clinical AE, as well as laboratory AE on visits 3, 5, 7, 14 and 28 after
vaccination. We measured CD4, CD8 T cells and CD4/CD8 ratio in all visits (Fig 1).
Clinical and laboratory AE were assessed as binary variables, defined as positive if the par-
ticipant had any clinical AE, or any clinically significant laboratory AE at visits 3, 5, 7, 14 or 28,
and negative otherwise. Laboratory AE were considered clinically significant if graded2
according to the National Institutes of Allergy and Infectious Diseases’ Division of AIDS
Table for Grading the Severity of Adult and Pediatric AE [32]. Viremia by YFV virus was
assessed both as numeric and binary variable. The binary variable for YFV viremia was defined
as positive if the participant had a detectable measurement (>200 copies/ml) on days 3, 5, 7 or
14 after vaccination, and negative otherwise.
Laboratory methods
The HIV VL was determined by reverse-transcriptase (RT)-PCR using Amplicor HIV-1 Moni-
tor Test (Roche Diagnostic Systems, NJ, USA), with a lower detection limit of 40/mm3. CD4
and CD8 T cell counts were determined by flow cytometry (FACSCalibur, BD Biosciences,
CA, USA) using Multitest reagent (BD Biosciences).
Kynurenine and tryptophan were quantified on cryopreserved plasma samples by liquid
chromatography–tandem mass spectrometry as previously described [33].
Human Pegivirus RNA was extracted from 140μl serum samples using QIAamp Viral RNA
Mini Kit (QIAGEN Inc., California, USA), according to manufacturer’s instructions. A 5μl ali-
quot of extracted RNA was used to perform qRT-PCR with SuperScript III Platinum One-Step
Quantitative RT-PCR System with ROX kit (Life Technologies), with primers and a TaqMan
probe that amplified and quantified a fragment of 72-bp of the 5’ untranslated region (5’UTR).
Fig 1. Overview of study procedures. YFV, Yellow Fever vaccine; NAb, neutralizing antibodies; KT, kynurenine/
tryptophan; CBC, complete blood count; HIV, human immunodeficiency virus; AE, adverse events
doi:10.1371/journal.pntd.0005219.g001
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The reaction was made with 0.5μl of SuperScript III RT/Platin Taq Mix, 12.5μl of 2X Reaction
Mix with ROX, 0.75μl of 10μM Forward primer RTG1 (5’GTGGTGGATGGGTGATGACA3’)
(Sigma), 1.25μl of 10μM Reverse primer RTG2 (5’GACCCACCTATAGTGGCTACCA3’)
(Sigma), 0.4μl of 25 μM TaqMan probe ([6’FAM]CCGGGATTTACGACCTACC [TAMRA-
6-FAM]) (Life Technologies), and reaction final volume of 25μl was completed with DEPC-
treated water. cDNA synthesis was performed during the first 15 minutes at 50˚C. After 2 min-
utes at 95˚C, amplification and quantification were performed during 40 cycles with the fol-
lowing times and temperatures: 95˚C, 15 seconds; 60˚C, 30 seconds. The reading of FAM
fluorescence was made during annealing period at 60˚C.
For measurement of YFV viremia, total RNA was extracted from 140μl of plasma using
QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany) and eluted in 60μl of elution buffer.
cDNA was obtained through RT reaction using 10μl of extracted RNA, 300ng of random
primer (Amersham Biosciences, Piscataway, NJ, USA); 10U/μl of Super Script II RT (Invitro-
gen, Carlsbad, CA, USA) in a buffer solution with 0.25U/μl of ribonuclease inhibitor (Invitro-
gen) and 0.5mM deoxyribonucleotide triphosphates (Invitrogen), at final volume of 20μl. The
reaction was incubated at 45˚C for 90 minutes. Five μl of cDNA was added to 20μl of TaqMan
Master Mix (Applied Biosystems, Foster City, CA, USA) and amplified by RT-PCR using the
following primers and probe: (YF-NS5_F) 5’-GCACGG ATGTAACAGACTGAAGA-3’; (YF-
NS5_R) 5’-CCAGGCCGAACCTGTC AT-3’ and (YF-NS5Probe) 5’-FAM-CGACTGTGTGG
TCCGGCCCATC-3’–TAMRA [34]. The product was amplified using optical detection system
layout of BioRad ICycler for 45 cycles at the following settings: 10 min, 95˚C; 45 cycles of 15s
for 94˚C and 60s for 60˚C.
NAb titers against YF virus were measured by Plaque Reduction Neutralization Test (PRNT)
performed at Virologic Technology Laboratory of Bio-Manguinhos (LATEV, FIOCRUZ, Rio
de Janeiro) as previously described [16].
Ethical aspects
The study was approved by the Ethics Committee at Clinics Hospital in University of Sao
Paulo. Upon participation, all participants signed an informed consent form. HIV tests were
performed with pre and post-test counseling, and all individual identifiable information was
maintained in secured cabinets and electronic files.
Statistical analysis
Groups were compared using Wilcoxon rank-sum test for continuous variables and Fisher’s
exact test for categorical variables. Titers of YF-specific NAb, CD4 and CD8 T cell counts were
log-transformed to approximate normal distribution, and antilog transformation was required
for model interpretation.
The effect of HIV status on levels of YFV viremia, and on initial YFV immunogenicity were
investigated using mixed models with robust standard errors, adjusted for age, sex, previous
YFV and interaction between HIV and visits. The effect of HIV status on persistence of YFV
immunogenicity was investigated using a linear regression model adjusted for age, sex, previ-
ous YFV and baseline values of YF-specific NAb titers.
The effects of T CD4 and T CD8 cell count, detectable HIV VL, CD4/CD8 ratio, KT ratio, and
Human Pegivirus viremia on YF-specific NAb titers among HIV-infected patients were investi-
gated using mixed models adjusted for age, baseline NAb titers and HIV VL. Correlations between
NAb titers and CD4/CD8 ratio or KT ratio were explored using Spearman rank correlation.
For all analysis, we assumed a two-sided alpha error of 0.05. All analyses were performed in
Stata version 13.1 (StataCorp. College Station, TX: StataCorp LP).
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We calculated sample size based on the impact of HIV status on titers of YF-specific NAb
in the first 3 months following vaccination, using estimates of effect size and standard devia-
tion from a prior study published by our group [16]. Since the analysis plan included mixed
models for repeated outcomes, we assumed a 20% reduction in error variance and estimated a
final sample of 33 participants per group using conventional means comparison.
Results
Between October 2011 and April 2014, 63 participants were enrolled. Enrollment of a greater
number of participants was compromised due to high refusal rates, mainly because most poten-
tial participants were referred to receive the YFV for a scheduled trip to an YF endemic area,
and were therefore planning to be out of town and unable to attend the study visits. In addition,
many potential participants refused participation due to the busy visit schedule, particularly in
the first 2 weeks of follow-up. After exclusion of five controls and one HIV-infected participant
due to missing visits, our final cohort included 12 HIV-infected and 45 HIV-uninfected individ-
uals. All participants in the HIV-infected group were men, 11 (92%) were under ART and 8
(67%) had undetectable (<40 copies/ml) HIV VL. Participants under ART with detectable HIV
VL had a range of 43–1,982 HIV copies/ml, and the only untreated participant had 110,531
HIV copies/ml at baseline. HIV-infected participants were more likely than -uninfected partici-
pants to be male and tended to be younger; 4 (33%) reported a prior YFV at a median of 14.5
years before enrollment (interquartile range [IQR] 10.5–21.5); none had received more than
one YFV shot. Among HIV-uninfected participants, 16 (36%) reported a prior YFV at a median
of 12 years before enrollment (interquartile range [IQR] 11–20); 10 had received a single shot
and 6 (13%) had received two YFV shots in lifetime. Groups had similar YF NAb titers at enroll-
ment, whether all participants or only participants with a prior YFV were considered (Table 1).
Baseline CD4 T cell count was high among HIV-infected participants (median 722 cells/mm3,
[IQR] 526–795), although still significantly lower than controls (median 941 cells/mm3, IQR
Table 1. Baseline characteristics of participants*
HIV-infected Controls p-value
N = 12 N = 45
Age–years 33 (30–47) 43 (31–62) 0.12
Male gender—N (%) 12 (100) 22 (49) 0.001
Previous YFV–N (%) 4 (33) 16 (36) 0.56
Single lifetime YFV dose 4 (33) 10 (22)
Two lifetime YFV doses 0 6 (13)
YF NAb, Log10mIU/mL
All participants 0 (0–3.0) 2.4 (0–3.3) 0.48
Participants with prior YFV 3.3 (2.9–4.0) 3.4 (3.2–4.0) 0.71
CD4 T count–cells/mm3 722 (526–795) 941 (807–1470) 0.003
CD4/CD8 ratio 0.7 (0.5–0.8) 1.6 (1.3–2.6) <0.0001
KT ratio–nM/μM 35.9 (33.4–43.9) 31.3 (27.5–37.7) 0.06
Viremia by Human Pegivirus–N (%) 8 (66.7) 12 (26.7) 0.016
Undetectable# HIV VL–N (%) 8 (67) - -
HIV, human immunodeficiency virus; YFV, Yellow Fever Vaccine; YF NAb, Yellow Fever-specific neutralizing antibodies; KT, kynurenine/tryptophan; VL,
viral load.
*Continuous variables are presented as medians and interquartile ranges.
#Considered undetectable if below 40 copies/ml.
doi:10.1371/journal.pntd.0005219.t001
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807–1470; p = 0.003). As expected, CD4/CD8 ratio was lower among HIV-infected participants
(median 0.7, IQR 0.5–0.8) compared to controls (median 1.6, IQR 1.3–2.6; p<0.0001). KT ratio
was also higher in HIV-infected group, but the difference did not reach statistical significance
(median 35.9 versus 31.3 nM/μM, p = 0.06). Viremia by Human Pegivirus was more prevalent
in HIV-infected (67%) than in -uninfected group (27%, p = 0.016, Table 1).
During study visits, HIV-infected subjects had no substantial change in CD4 T cell count
compared to baseline values (Fig 2A). HIV-infected participants who had detectable HIV VL
at baseline had no meaningful change in HIV VL across visits (Fig 2B). Among the 8 partici-
pants with undetectable HIV VL at baseline, only one had a detectable value (51 copies/ml) at
visit 84. HIV-infected participants had no change in ART status during follow-up.
AE following vaccination and the effect of HIV on viremia by the YFV
virus
Any clinical AE was reported by 6 (50%) participants in the HIV-infected group, and 22
(48.9%) controls. All reported clinical AE (local pain, tenderness and redness; nausea, myalgia,
fatigue, dizziness and fever) were mild and self-limited, as were laboratory AE–anemia, neu-
tropenia, lymphopenia, thrombocytopenia and liver enzymes elevation–which were detected
in 3 (25%) individuals in the HIV-infected group, and 13 (28.9%) controls.
Viremia by the YFV virus was detected in at least one visit in 40% of HIV-infected partici-
pants and 34% of controls. Maximum detected viremia was 11210 copies/mL in one HIV-
uninfected participant at day 5 after vaccination; in the HIV-infected group, highest measured
viremia was also observed at day 5 (4197 copies/mL). HIV status was not statistically associated
with levels of viremia by the YFV virus (p-value = 0.99 for the overall effect of HIV on YFV
viremia on days 3, 5, 7 and 14).
Effect of HIV status on initial YFV immunogenicity
At baseline, 4 HIV-infected participants (33%) and 17 controls (38%) had levels of NAb con-
sidered seropositive for a cutoff of 794 mUI/mL as defined by the referent laboratory [35]. If
only participants with a previous YFV were considered, 3 HIV-infected (75%) and 15 controls
(94%) had seropositive NAb titers. At 28 days after vaccination, all participants in both groups
were seropositive for YF, and at one year following vaccination, 11 HIV-infected participants
(92%) and 43 controls (96%) maintained seropositive YF-specific NAb.
We failed to find a statistically significant difference between groups defined by HIV status
on initial YFV immunogenicity in either visit individually or overall in a mixed model adjusted
for age, sex and previous YFV (Table 2). The model predicted lower YF-specific NAb titers for
women; in average, women had 0.33 times the titers observed for men (95% CI 0.17–0.66,
p = 0.002). As expected, compared to individuals without previous YFV, those who reported a
previous YFV had higher NAb titers (fold change 13.69, 95% CI 7.12–26.30, p<0.001).
Effect of HIV status on persistence of YFV immunogenicity
Persistence of YFV immunogenicity was significantly lower in HIV-infected participants com-
pared to controls in a mixed model adjusted for age, sex, previous YFV and baseline NAb
titers. In average, HIV-infected individuals had 0.32 times the NAb titers observed for HIV-
uninfected participants at one year after vaccination (95% CI 0.13–0.83, p = 0.021). We found
no statistically significant effect of age, sex or previous YFV on persistence of NAb (Table 3).
Predictors of Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients
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Predictors of YFV immunogenicity among HIV-infected participants
In the exploratory analysis restricted to HIV-infected patients, higher CD4/CD8 ratio and
lower KT ratio predicted higher YF-specific NAb titers; in average, for each 10% increase in
Fig 2. CD4+ T cell counts for HIV-infected participants (N = 12) across study visits (Panel A) and HIV VL across visits for participants
with VL above the limit of detection at baseline (N = 4, Panel B). Individual subjects are represented by distinct lines in the graph.
doi:10.1371/journal.pntd.0005219.g002
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CD4/CD8 ratio, post-baseline NAb titers were 21% higher (95% CI 3–38%, p = 0.024), and for
each 10% increase in KT ratio, post-baseline NAb titers were 21% lower (95% CI 5–37% lower,
p = 0.009) after adjustment for age, baseline NAb titers and HIV VL. There was no evidence for
an association between CD4 or CD8 T cell count and YFV immunogenicity (multiplicative
effect per 10% increase 1.05, 95% CI 0.91–1.20, p = 0.469, and 0.95, 95% CI 0.86–1.04, p = 0.295,
respectively) or between Human Pegivirus co-infection and YFV immunogenicity among HIV-
infected individuals (fold change 0.65, 95% CI 0.09–4.47, p = 0.659, Table 4). Adjusted for age
and baseline NAb titers, having detectable plasma HIV was associated with 60% lower YF-spe-
cific NAb titers (fold change 0.40, 95% CI 0.21–0.75, p = 0.004).
As to confirm the effects of CD4/CD8 ratio and KT ratio on NAb titers, we performed sim-
ple non-parametric correlation tests; as expected, CD4/CD8 ratio correlated positively with
NAb titers in all time-points, with statistically significant correlation in visit 28 (Rho = 0.74,
p = 0.0139) and visit 365 (Rho = 0.9, p = 0.0374). Similarly, KT ratio correlated negatively with
NAb titers in all time-points, with statistically significant correlation in visit 56 (Rho = -0.76,
p = 0.0171).
Discussion
In this prospective cohort of individuals receiving YFV, those with HIV had similar levels of
YFV viremia and AEs as HIV-uninfected controls. Compared to controls, HIV-infected
Table 2. Effect of HIV status on initial immunogenicity after YFV
Predicted multiplicative effect in YF-specific NAb 95% CI p-value
Age (per year increase) 1.00 0.98 to 1.02 0.82
Female sex 0.33 0.17 to 0.66 0.002
Previous YFV 13.69 7.12 to 26.30 <0.001
HIV status
Overall HIV effect across visits 0.25
Baseline 0.19 0.03 to 1,24 0.08
Day 7 0.95 0.11 to 8.35 0.96
Day 14 0.60 0.10 to 3.55 0.57
Day 28 0.66 0.21 to 2.08 0.47
Day 56 0.67 0.19 to 2.35 0.53
Day 84 1.06 0.36 to 3.08 0.92
HIV, human immunodeficiency virus; YFV, Yellow Fever vaccine; NAb, neutralizing antibodies
Model adjusted for age, sex and previous YFV
doi:10.1371/journal.pntd.0005219.t002
Table 3. Effect of HIV status on persistence of YFV immunogenicity
Predicted multiplicative effect in YF-specific NAb 95% CI p-value
Age (per year increase) 1.01 0.96 to 1.07 0.57
Female sex 0.54 0.12 to 2.50 0.42
Previous YFV 1.27 0.25 to 6.48 0.77
Baseline YF-specific NAb 1.08 0.63 to 1.85 0.78
HIV infection 0.32 0.13 to 0.83 0.021
HIV, human immunodeficiency virus; YFV, Yellow Fever vaccine; NAb, neutralizing antibodies
Model adjusted for age, sex, previous YFV and baseline values of YF-specific NAb titers
doi:10.1371/journal.pntd.0005219.t003
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participants also had similar initial immunogenicity to YFV, measured by YF-specific NAb
titers at 7, 14, 28, 56, and 84 days after vaccination, adjusted for age, sex and previous YFV.
However, HIV status was independently associated with lower persistence of YF-specific NAb
titers one year after vaccination. In the analysis of predictors of immunogenicity among HIV-
infected participants, lower CD4/CD8 ratio, higher KT ratio and detectable HIV VL were asso-
ciated with lower YF-specific NAb titers. There was no evidence for an association between
viremia by Human Pegivirus, CD4 and CD8 T cell counts and YF-specific NAb titers among
HIV-infected individuals.
Earlier studies of YFV immunogenicity including HIV-infected patients in the pre-ART
period or in the initial phases of ART had demonstrated that CD4 T cell count and HIV VL
predicted YF-specific NAb titers [7–12]. However, in the current era of early ART initiation,
more HIV-infected patients are expected to have undetectable HIV VL and higher CD4 T cell
counts. In our study, despite the elevated CD4 T cell count and high proportion of ART-sup-
pressed individuals, HIV status was still associated with lower persistence of YF-specific NAb
titers following an apparently adequate initial immunogenicity. Our results are consistent with
prior publications suggesting that HIV-infected subjects still present lower responses to vac-
cines [1, 6, 16]. In addition, while the START and TEMPRANO trials demonstrated that ear-
lier ART initiation dramatically reduces the risk of infectious outcomes, there was still a
substantial risk of infectious outcomes in the immediate ART arms [36, 37]. Thus there are
likely to be subtle immune defects that persist despite early ART initiation. Our study provides
potentially important insights into mechanisms that might contribute to this persistent risk of
infectious complications as well as point of care diagnostics that might identify patients at
highest risk. For example, higher plasma KT ratio–a marker of IDO activity–strongly predicted
lower YFV Nab titers after vaccination. While our observational study cannot assess causality,
the fact that IDO-generated tryptophan catabolites suppress lymphocyte proliferation and
function provides a plausible mechanistic pathway of its detrimental effect on vaccine respon-
siveness and, more broadly, adaptive immunity. Indeed, higher IDO activity has already been
shown to predict increased mortality in several cohorts of ART-suppressed HIV-infected indi-
viduals [38–40]. While higher IDO activity might simply be a surrogate of other immunologic
defect causally associated with impaired B cell function (e.g., the extent of T follicular helper
cell infection and/or dysfunction in lymphoid tissues), a potential causal role for IDO activity
in impairing vaccine responsiveness is plausible. Interestingly, high KT ratio was one of the
strongest immunologic correlates of low CD4/CD8 ratio in another recent study of ART-sup-
pressed individuals [21], suggesting that this biomarker–already obtained as part of routine
Table 4. Predictors of YFV immunogenicity in HIV-infected participants
Unadjusted multiplicative effect in YF-NAb 95% CI Adjusted multiplicative effect in YF-NAb# 95% CI p-value
CD4 T count* 1.07 0.96 to 1.18 1.05# -1.08 to 1.17 0.47
CD8 T count* 0.98 0.89 to 1.06 0.95# 0.86 to 1.04 0.30
CD4/CD8 ratio* 1.12 0.68 to 1.23 1.21# 1.03 to 1.38 0.024
Human Pegivirus 1.12 0.21 to 5.90 0.65# 0.09 to 4.47 0.66
KT ratio* 0.86 0.20 to 0.74 0.79# 0.63 to 0.95 0.009
Detectable HIV VL 0.36 0.20 to 0.67 0.40§ 0.21 to 0.75 0.004
YFV, Yellow Fever vaccine; HIV, human immunodeficiency virus; NAb, neutralizing antibodies; KT, kynurenine/tryptophan; VL, viral load
*Effect per each 10% increase in the predictor
#Model adjusted for age, baseline NAb titers and HIV VL
§Model adjusted for age and baseline NAb titers
doi:10.1371/journal.pntd.0005219.t004
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clinical care—might help identify individuals with highest risk of impaired vaccine responses
and adaptive immune defects.
Collectively, our findings further encourage the development of therapeutic interventions
to reduce immune activation in ART-treated HIV-infected individuals [18, 20]. Early ART ini-
tiation is a well-recognized, yet insufficient strategy to normalize persistent immune activation
[41], and additional strategies including inhibition of IDO activity are currently under study
[42].
While effective interventions to inhibit immune activation are not available for clinical use,
another important implication of our findings is the potential to substantiate recommenda-
tions for a booster dose of YFV for HIV-infected individuals at permanent or recurring risk of
wild YF. In a recent publication, the Advisory Committee on Immunization Practices from
Centers for Disease Control and Prevention published recommendations for YFV, suggesting
HIV-infected individuals may benefit from a booster vaccination, which would not be recom-
mended in routine circumstances due to the high immunogenicity and durability of YFV in
the general population [43]. Our results suggest that a booster YFV may be beneficial even for
HIV-infected individuals with high CD4 T cell counts. Since lower persistence of NAb was
observed one year after YF vaccination, and AE following a booster dose of YFV are rare [28,
29], either periodic monitoring of YF-NAb or administration of a booster YFV dose could be
recommended for HIV-infected individuals at permanent or recurring risk of wild YF as early
as one year after primary vaccination. Additional studies are necessary to determine the dura-
bility of immunogenicity after a booster vaccination in this population.
Because all included participants received YFV as indicated due to potential risk of expo-
sure to wild-type virus, we cannot rule out that natural exposure, rather than YFV alone, par-
tially accounted for the observed NAb titers. However, most participants were residents in
non-endemic areas and received YFV due to temporary visits to endemic regions with low risk
of natural exposure. Furthermore, this potential competing immune stimulus would likely
occur non-differentially regarding HIV status. Consequently, we do not believe our results are
substantially compromised by natural exposure to wild YF virus.
Due to the small sample size, our results must be interpreted with caution. The model
addressing predictors of YFV immunogenicity among HIV-infected participants included
only 12 individuals followed longitudinally with 7 repeated outcome measurements. Although
statistical methods for longitudinal analysis typically reduce error variance and improve
power, this exploratory analysis needs confirmation in larger samples and different settings. In
addition, our study was likely underpowered to provide definitive conclusions regarding the
effect of HIV status on initial YFV response, on risk of AE (in particular rare severe AE) and
on viremia by the YFV virus. Sensitivity for detection of AE was enhanced in our study by the
measurement of solicited clinical AE, laboratory assessment of potential hematological or bio-
chemical abnormalities, and systematic measurement of YFV viremia. Therefore, although not
definitive, our findings provide important information on YFV clinical and laboratory adverse
events, as well as vaccine virus kinetics among HIV-infected participants.
Our study may also be underpowered to detect significant effects of viremia by Human
Pegivirus, CD4 and CD8 T cell counts on YF-specific NAb titers among HIV-infected partici-
pants. Our study included HIV-infected individuals with a very high range of CD4 T cell
count, and we cannot rule out that CD4 T cell count would still predict YFV immunogenicity
among patients with wider CD4 T cell count variability. Finally, we used a single measurement
of RT-PCR to determine Human Pegivirus co-infection, and were unable to discriminate
recent unresolved infections from chronic infections.
In conclusion, HIV-infected individuals have impaired NAb response to YFV due to a
poorer persistence of antibodies, despite a seemingly normal initial response. Immune
Predictors of Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005219 December 12, 2016 11 / 15
activation seems to reduce YFV immunogenicity, consistent with the observation that immune
activation markers are useful predictors of clinical outcomes in the current era of HIV care
[21, 22, 38]. A booster dose of YFV, although not recommended in routine circumstances,
may be beneficial for HIV-infected individuals at permanent or recurring risk of wild YF.
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